Skip to main content

Updated information on SARS-CoV-2 Variants of Concern (VOC)

Virus evolution is an expected biologic characteristic of SARS-CoV-2, and the longer SARS-CoV-2 persists, the more opportunities it has to evolve. While most genetic variants are of little-to-no consequence, certain attributes could prolong the pandemic and reintroduce risk of COVID-19 even among vaccinated individuals.

The World Health Organization (WHO) defines classes of SARS-CoV-2 variants based on severity of illness, transmissibility, and their impact on public health and social countermeasures such as lockdowns and masking, and medical countermeasures such as diagnostics, therapeutics, and vaccines. Variants of Concern (VOC) are those with evidence of inducing more severe disease, increasing transmissibility, or having an impact on countermeasures.

There are currently four VOC identified by the WHO. Variants of Interest (VOI) are those with genetic changes that are suspected to affect transmission, diagnostics, therapeutics, or immunity, but without direct evidence that they do so (yet). Seven VOI are being tracked globally and investigated for potential escalation to VOC. The Centers for Disease Control and Prevention (CDC) also define Variants of High Consequence (VHC) as variants with clear evidence of significantly reduced effectiveness of medical countermeasures, though none are classified as VHC at this time.

Update to naming convention

Because of the confusing Phylogenetic Assignment of Named Global Outbreak (PANGO) lineage numbering system and various other scientific naming conventions, most variants have been known colloquially by their country of original detection such as the U.K. variant or South African variant, which can be stigmatizing and discriminatory. In response, the WHO assigned Greek letters to VOC and VOI, though research efforts will still include the scientific naming conventions.

WHO label

PANGO lineage

First identified

Attributes

Alpha

B.1.1.7

United Kingdom (September 2020)

  • ~50% increased transmission
  • Potential increased severity

Beta

B.1.351

South Africa
(May 2020)

  • ~50% increased transmission
  • Significant reduction in efficacy of some monoclonal antibody therapies
  • Reduced neutralization by convalescent and post-vaccination antibodies

Gamma

P.1

Japan/Brazil
(November 2020)

  • Significant reduction in efficacy of some monoclonal antibody therapies
  • Reduced neutralization by convalescent and post-vaccination antibodies

Delta

B.1.617.2

India
(October 2020)

  • Increased transmissibility
  • Potential reduction in efficacy of some monoclonal antibody therapies
  • Potential reduction in neutralization by convalescent and post-vaccination antibodies

Alpha variant

First identified in September 2020, it is currently circulating in 170 countries. It is about 50 percent more transmissible than the original SARS-CoV-2 strain and while there have been conflicting reports, it appears that Alpha may cause more severe disease with greater risk of mortality. However, the Alpha variant is neutralized by therapeutic monoclonal antibodies and antibodies generated after vaccination or recovery from COVID-19, suggesting that the risk of reinfection or breakthrough infection after vaccination is low.

Beta variant

The first variant to be identified in this class in May 2020, Beta was granted designation of VOC status in December. It is associated with enhanced transmissibility and has been detected in 119 countries. Perhaps most concerning is that the Beta variant is associated with reduced efficacy of monoclonal antibody therapy and vaccination. Reinfection after COVID-19 is also possible as neutralization by convalescent serum is reduced.

Gamma variant

There is some debate over whether this variant is associated with increased transmissibility. However, Gamma is able to evade neutralization by antibodies (monoclonal therapies and those induced by SARS-CoV-2 infection or vaccination), increasing the risk of reinfection and breakthrough infection.

Delta variant

This is the newest to be escalated to variant of concern status. Delta was responsible for India’s devastating second wave and contributed to prolonging lockdown restrictions despite widespread vaccination in the U.K. Due to its increased transmissibility and reduced efficacy of infection- and vaccine-induced antibodies, it is expected to become the dominant strain globally.

Global vaccination –– as quickly and broadly as possible –– remains the most important pandemic countermeasure to bring case numbers down and restrict the evolution of new variants. Public health and social measures, including lockdowns and masking, are still needed in certain areas and may be reinstituted in locations with new community spread of variants. Booster vaccines that target variant strains are currently being investigated, but whether they will be needed (globally or locally) remains unclear. Global genetic surveillance remains essential to track the spread of existing variants and to identify new variants for evaluation.

 

For more information, see the topic COVID-19 (Novel Coronavirus) in DynaMed

Original article published on EBSCO Health Notes. Written by:

  • Vito Iacoviello, MD, Deputy Editor for Infectious Disease, Allergy, and Immunology at DynaMed; and
  • Heather D. Marshall, PhD, Public Health Content Manager at DynaMed.

CMA members have access to DynaMed, a point-of-care reference tool valued at US$399 per year, as part of their membership.

Do you have a question on COVID-19 or another clinical topic? Contact the Ask a Librarian team to request a literature search.

About the author(s)

DynaMed is a clinician-focused tool designed to facilitate efficient and evidence-based patient care. Rigorous, daily review of medical literature by physician and specialist staff ensures timely and objective analysis, synthesis and guidance. DynaMed includes drug content from Micromedex, Canadian and international guidelines, and clinical images. CMA members have access to DynaMed, a point-of-care tool, included with their membership ― a tool valued at US$399 a year.